AstraZeneca said its experimental antibody tozorakimab met primary goals in two Phase 3 trials in chronic obstructive pulmonary disease, delivering flare-up reductions across a broad population. The company’s Oberon and Titania studies included former and current smokers and patients across eosinophil counts and COPD severity stages, and the results were described as a surprise by analysts given prior setbacks in mid-stage testing. The antibody blocks IL-33 signaling via a “reduced” form mechanism intended to avoid interactions tied to disappointing clinical history in the class. AstraZeneca did not release complete trial data, pointing to upcoming medical-meeting disclosure, which is expected to shape expectations for regulatory review and uptake. If approved, tozorakimab could expand the biologics-eligible population beyond current eosinophil-restricted labels, increasing competitive pressure on established COPD immunotherapies.